56. ベーチェット病 Behcet disease Clinical trials / Disease details


臨床試験数 : 81 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02258867
(ClinicalTrials.gov)
November 20142/10/2014Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisA Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease UveitisBehcet's Disease UveitisDrug: Placebo;Drug: GevokizumabXOMA (US) LLCNULLTerminated18 YearsN/ABoth4Phase 3United States
2EUCTR2012-001125-27-GB
(EUCTR)
15/01/201312/09/2012Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitisEYEGUARD TM -B Behçet’s disease uveitis
MedDRA version: 18.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
INN or Proposed INN: gevokizumab
Other descriptive name: XOMA 052
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
60Phase 3Portugal;Hong Kong;Saudi Arabia;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of
3EUCTR2012-001125-27-PT
(EUCTR)
04/01/201313/09/2012Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis - EYEGUARD TM-B Behçet’s disease uveitis
MedDRA version: 18.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
INN or Proposed INN: gevokizumab
Other descriptive name: XOMA 052
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
44Phase 3Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of
4EUCTR2012-001125-27-IT
(EUCTR)
26/11/201221/09/2012Efficacy of gevokizumab in the treatment of patients with Behcet`s disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis. The EYEGUARD B study. - THE EYEGUARD TM B STUDY Behçet's disease uveitis
MedDRA version: 14.1;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders
MedDRA version: 14.1;Level: PT;Classification code 10046851;Term: Uveitis;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: GEVOKIZUMAB
Product Code: S78989
INN or Proposed INN: GEVOKIZUMAB
Other descriptive name: XOMA 052
INSTITUT DE RECHERCHES INTERNATIONALES SERVIERNULLNot RecruitingFemale: yes
Male: yes
110Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;Brazil;Tunisia;Germany;China;Korea, Republic of
5NCT01965145
(ClinicalTrials.gov)
November 201217/9/2013Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease UveitisBehcet's UveitisDrug: Gevokizumab;Drug: PlaceboInstitut de Recherches Internationales ServierNULLTerminated18 YearsN/AAll84Phase 3Korea, Republic of;United Kingdom
6EUCTR2012-001125-27-ES
(EUCTR)
17/10/201202/10/2012Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis Behçet?s disease uveitis
MedDRA version: 14.1;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
INN or Proposed INN: gevokizumab
Other descriptive name: XOMA 052
Laboratorios Servier S.L.NULLNot RecruitingFemale: yes
Male: yes
110Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of
7EUCTR2012-001125-27-GR
(EUCTR)
03/10/201213/09/2012Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis Behçet’s disease uveitis
MedDRA version: 15.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
INN or Proposed INN: gevokizumab
Other descriptive name: XOMA 052
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
110Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of
8EUCTR2012-001125-27-DE
(EUCTR)
24/09/201212/09/2012Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitisEYEGUARD TM -B Behçet’s disease uveitis
MedDRA version: 17.1;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
INN or Proposed INN: gevokizumab
Other descriptive name: XOMA 052
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
44Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Germany;Tunisia;China;Korea, Republic of